VALNEVA SE - ADR

VALN represents the publicly traded equity of Valneva SE, a biotech company focused on developing and commercializing vaccines for infectious diseases. The stock provides investors with exposure to the vaccine development and manufacturing sector. VALN trades on the Nasdaq Global Select Market under the ticker symbol VALN. Investors can review the latest stock data and company updates on the VALN quote page.

VALN operates in the biotechnology industry, specifically within the vaccine development and manufacturing segment. The company focuses on creating vaccines for infectious diseases, including those with limited or no available preventative options. This industry is characterized by extensive research and development, regulatory hurdles, and long product development timelines, which can influence the stock's risk and reward profile.

Recent performance for VALN can be found in the price chart and performance metrics displayed on this page, which show changes over various periods such as one day, one week, one month, and year-to-date. For the most current and historical price movements, refer to the VALN stock page for up-to-date figures and trends.

Evaluating VALN's valuation involves examining metrics such as price-to-earnings (P/E) ratio, price-to-sales (P/S), and enterprise value-to-EBITDA, if applicable. For a pre-revenue or early-stage biotech, traditional earnings-based metrics may not be meaningful; instead, investors often focus on pipeline potential, cash runway, and comparisons to peers. The latest valuation data for VALN is available on this page, and investors should consider both quantitative and qualitative factors.

Key financial metrics for VALN include revenue growth, research and development expenses, operating cash flow, and cash and cash equivalents. These metrics help assess the company's ability to fund its pipeline and achieve profitability. Additionally, investors may monitor product revenue, gross margins, and partnership milestones. For current figures, refer to VALN's latest financial statements and earnings reports.

Investing in VALN carries risks typical of clinical-stage biotechnology companies, including regulatory setbacks, clinical trial failures, and reliance on successful product commercialization. Other risks include competition, intellectual property challenges, and the need for additional financing, which may dilute shareholders. Market sentiment and broader economic conditions can also impact the stock. Investors should review VALN's risk disclosures in its SEC filings for a comprehensive overview.